RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/AVXL-Info-Request-Form-1048. There is no cost or obligation to you.
According to the complaint, Anavex issued misleading statements and failed to disclose that the Company had used a paid stock promoter to artificially inflate the Company’s share price.
On December 29, 2015, Anavex disclosed that it had received a subpoena from the SEC on December 22, 2015. Anavex stated, in part, that “[t]he Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares.” Then on December 30, 2015, Seeking Alpha published a report entitled “Anavex: A Regulatory Target Damaged By Incriminating Evidence.” On this news, Anavex stock fell $0.78, or 12.42%, to close at $5.50 per share.
If you suffered a loss in Anavex Life Sciences you have until February 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/AVXL-Info-Request-Form-1048.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
